Conference Description:

Built from research with the FDA, EMA and Gilead, the 2nd Annual NASH Summit Europe will once again elevate industry-to-industry dialogue and reveal leading insights in overcoming the hurdles limiting NASH therapeutic success.

Join the NASH community as they collectively address the biggest challenges in NASH through a tighter lens including the potential for stand-alone versus combination therapeutics, the genetic drivers influencing disease heterogeneity and the future payer and reimbursement landscape.

Hear from 22 stakeholders including Pfizer, Novartis and MedImmune as this exclusively drug development driven forum equips you with the connections and actionable takeaways you need to capture one of many market opportunities for a successful NASH candidate.

Tickets https://go.evvnt.com/242368-1? pid=154
Brochure https://go.evvnt.com/242368-3?pid=154

Prices:
GOLD: Conference + 2 Workshops (Early Bird - Ends 10/08/2018) EUR 2797.0
GOLD: Conference + 2 Workshops EUR 2997.0
SILVER Conference + 1 Workshop (Early Bird - Ends 10/08/2018) EUR 2298.0
SILVER Conference + 1 Workshop EUR 2498.0
BRONZE Conference Only (Early Bird - Ends 10/08/2018) EUR 1799.0
BRONZE Conference Only EUR 1999.0
Workshops Only EUR 599.0

Speakers: Adil Mardinoglu, (Assistant Professor of Systems Biology, Royal Institute of Technology (KTH)), Aimo Kannt, (Cluster Head Comorbidities & Complications of Diabetes, ,Sanofi), Andreas Geier, (Head of Hepatology ,University of Wurzburg), Bill Esler, (Senior Director ,Pfizer), David Fraser, (Chief Scientific Officer ,NorthSea Therapeutics), Dimitar Tonev, (Honorary Consultant ,HCV Research UK),Donna Cryer, (President & Chief Executive Officer ,Global Liver Institute), Donny Wong, (Global Analytics & Insight Lead, CVRM Early Assets ,AstraZeneca), Eric Hughes, (Head of Global Development Franchise, Immunology & Dermatology ,Novartis), Jonathan Roth, (Senior Director, Head Preclinical & Translational Biology ,Mistral Therapeutics), Gabriel Baverel, (President & Chief Executive Officer ,Metabolys), Henning Grønbæk, (Professor Internal Medicine & Hepatology ,Aarhus University), Meena Jain, (Director, Clinical Development, Cardiovascular & Metabolic Disease, MedImmune), Nikolai Naoumov, (Executive Director, Hepatology Science & Innovation, Novartis), Pietro Scalfaro, (Chief Medical Officer ,Enyo Pharmaceuticals), Rebecca Taub, (Chief Medical Officer, Executive Vice President Research & Development ,Madrigal Pharmaceuticals), Richard Lee, (Director,Ionis Pharmaceuticals), Sebastien Bolze, (Chief Scientific Officer, Poxel Pharmaceuticals), Sophie Mégnien, (Chief Medical Officer ,Genfit), Stephen Rossi, (Senior Director, Clinical Development & Medical Affairs ,NGM Biopharmaceuticals) ,Suneil Hosmane, (Executive Vice President – Strategic Development ,Genfit)

Time: on Monday October 22, 2018 at 8:00 am (ends Wednesday October 24, 2018 at 5:30 pm)